ReviewNeurology. Clinical practice2018
Lower prevalence of multiple sclerosis in First Nations Canadians.
Review in Neurology. Clinical practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 12 citations in OpenAlex.
- Multiple Sclerosis: An Ethnically Diverse Disease with Worldwide Equity Challenges Accessing Care.Neurology international · 2025Article
- Article
- Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Diversity, Equity, and Inclusion in the Multiple Sclerosis Community: A Call to Action.International journal of MS careArticle
- Characterizing the diversity of the multiple sclerosis population in Canada: A scoping review.Multiple sclerosis journal - experimental, translational and clinicalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe compared the incidence and prevalence of multiple sclerosis (MS) between First Nations (FN) and non-FN populations in Manitoba.
methodsWe applied previously validated algorithms to population-based administrative (health claims) data from Manitoba, Canada, to identify all persons with MS from 1984 to 2011. We identified FN individuals using the Municipality of Registration field held at Manitoba Health. We compared the incidence and prevalence of MS between the FN and non-FN populations using negative binomial models.
resultsFrom 1984 to 2011, 5,738 persons had MS, of whom 64 (1.1%) were of FN ethnicity. The average annual incidence rate per 100,000 population was 8.15 (95% confidence interval [CI] 5.98-11.1) in the FN population and 15.7 (95% CI 15.1-16.3) in the non-FN population (incidence rate ratio 0.52; 95% CI 0.38-0.71). In 1984, the crude prevalence of MS per 100,000 population was 35.8 (95% CI 14.9-86.1) in the FN population and 113.3 (95% CI 106.3-120.8) in the non-FN population. Between 1984 and 2011, the age-standardized prevalence of MS increased by 351% to 188.5 (95% CI 146.6-230.4) in the FN population. In contrast, the prevalence of MS per 100,000 general population increased by 225%-418.4% (95% CI 405.8-431.0).
conclusionsThe incidence and prevalence of MS are twofold lower in the FN population than the non-FN population. Nonetheless, the prevalence of MS in FN Manitobans is higher than in other indigenous populations outside Canada. Given reports of more rapid disability progression among FN Canadians with MS, and the rising prevalence of MS in this population, attention should be directed to the needs of this population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.